NCT04638309View on ClinicalTrials.gov

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

April 25, 2022

Study Completion Date

April 25, 2022

Conditions
MDSMyelodysplastic Syndromes
Interventions
DRUG

APR-548 + Azacitidine

APR-548 monotherapy period followed by APR-548 in combination with Azacitidine

Trial Locations (4)

33612

H. Lee Moffitt Cancer Center, Tampa

77030

MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institue, Boston

Sponsors

Lead Sponsor

Aprea Therapeutics
All Listed Sponsors
lead

Aprea Therapeutics

INDUSTRY